David A. Siegel Sc Pharmaceuticals Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$8.94 - $11.74 $1.09 Million - $1.43 Million	-121,700 Reduced 87.12%	18,000 $183,000
Q1 2023 May 15, 2023	BUY	$5.59 - $9.47 $242,606 - $410,998	43,400 Added 45.07%	139,700 $1.27 Million
Q4 2022 Feb 14, 2023	BUY	$4.02 - $7.53 $387,125 - $725,139	96,300 New	96,300 $690,000
Q3 2021 Nov 15, 2021	SELL	$4.93 - $7.15 $54,230 - $78,650	-11,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.19 - $7.38 $3,633 - $5,166	-700 Reduced 5.98%	11,000 $67,000
Q1 2021 May 17, 2021	SELL	$5.65 - $7.66 $7,345 - $9,958	-1,300 Reduced 10.0%	11,700 $78,000
Q4 2020 Feb 16, 2021	SELL	$5.17 - $9.41 $10,340 - $18,820	-2,000 Reduced 13.33%	13,000 $69,000
Q3 2020 Nov 16, 2020	BUY	$7.12 - $8.86 $106,800 - $132,900	15,000 New	15,000 $112,000

37.1M

110K

12.1K

Ticker SCPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,402,100
Market Cap $92.9M
Description
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product p...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.